title: Should the newer oral anticoagulants be withheld from patients with valvular AF?
authors.affiliation: University of Arizona College of Medicine, Tucson, AZ. Electronic address: jdalenmd@gmail.com.
authors.forename: James E
authors.initials: JE
authors.lastname: Dalen
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000150:complications* / Q000188:drug therapy*; D001562:Benzimidazoles / Q000627:therapeutic use; D000069604:Dabigatran; D006349:Heart Valve Diseases / Q000150:complications*; D006801:Humans; D019934:International Normalized Ratio; D009025:Morpholines / Q000627:therapeutic use; D000069552:Rivaroxaban; D020521:Stroke / Q000517:prevention & control; D013876:Thiophenes / Q000627:therapeutic use; D014859:Warfarin / Q000627:therapeutic use; D015091:beta-Alanine / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D001562:Benzimidazoles; D009025:Morpholines; D013876:Thiophenes; D015091:beta-Alanine; D014859:Warfarin; D000069552:Rivaroxaban; D000069604:Dabigatran